Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.

Tadashi UwagawaTaro SakamotoTakeshi GochoHiroaki ShibaShinji OndaJungo YasudaYoshihiro ShiraiRyoga HamuraKenei FurukawaKatsuhiko YanagaToru Ikegami

Published in: PloS one (2022)

NAM/GEM/S-1 therapy is safe and could be promising option for unresectable pancreatic cancer, especially for stage IV cancer.

Keyphrases